I

Inotiv

Global CRO for life sciences research

Investigative and Molecular Pathology Coordinator

Full-Time
$60k - $68k
Mid
Bachelor's
Boulder, CO, USA
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor's degree or higher in life sciences.
  • Excellent organizational skills and attention to detail.
  • Professional communication and interpersonal skills, with the ability to work with personnel at all levels of the organization.
  • Ability to coordinate and collaborate with other functional departments and sites.
  • Ability to multitask and manage multiple projects simultaneously.
  • Ability to create, manage, track, and update histopathology deliverable schedules.
  • Ability to review study designs and protocols as they apply to scheduling histopathology work.
  • Proficiency with required computer software applications, including Word, Outlook, Excel, Smartsheet, and ESM.
  • Ability to read, write, speak, and understand English, scientific protocols, and reports.
  • Manual dexterity to operate a computer.
  • Ability to sit for prolonged periods and work at a computer, talk, stand, walk, make repetitive hand and finger movements, reach, and lift 10–20 pounds.
  • Ability to work in a typical interior office or laboratory environment.
Responsibilities
  • Follow all standard operating procedures and applicable laboratory or company policies and procedures.
  • Maintain confidential information.
  • Interact professionally with clients, employees, and the community.
  • Support and participate in company initiatives as directed.
  • Maintain thorough knowledge of facility standard operating procedures, policies, and study protocols.
  • Adhere to all safety regulations and procedures.
  • Provide assistance or support to other Inotiv sites.
  • Primarily support remote and on-site pathologists with study coordination and daily operational needs.
  • Provide secondary support to the DTS Project Management Team and DSA Program Management Team.
  • Lead meetings to maintain and communicate pathology project schedules, timelines, milestones, and priorities.
  • Coordinate pathology start-up by gathering required documents, data, materials, and study information before pathology work begins.
  • Maintain visibility of upcoming and active pathology projects and identify and communicate scheduling conflicts, risks, or missing information.
  • Organize and maintain study materials, records, and documentation across shared servers, Microsoft Teams, SharePoint, ESM, Smartsheet, HubSpot, and other required systems.
  • Support preparation of protocols, amendments, change orders, study updates, and other project documentation.
  • Coordinate internal and external shipments of study-related materials.
  • Assist with project status updates, meeting coordination, action-item tracking, and cross-functional communication.
  • Support revenue recognition activities and documentation as needed.
  • Ensure study documentation is complete, accurate, timely, and compliant with applicable standard operating procedures.
  • Use project-management tools and templates to track work, maintain records, and improve project visibility.
  • Identify opportunities to improve workflows, communication, scheduling, and document organization.
  • Perform other duties and special projects as assigned.
Desired Qualifications
  • Three or more years of relevant experience is preferred.

About the company

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Get referred to Inotiv

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 20, 2026 restructuring improved liquidity and strengthened Inotiv's balance sheet.
  • Q1 fiscal 2026 backlog reached $145.4 million, supporting near-term DSA revenue visibility.
  • Management kept normal operations through bankruptcy, preserving clients, vendors, and service continuity.

What critics are saying

  • June 2026 Chapter 11 cancelled existing equity, wiping out prior shareholders.
  • USDA cited Inotiv facilities in April 2026 and August 2026 for critical violations.
  • Animal-welfare scandals and bankruptcy stigma threaten customer trust and future contract wins.

What makes Inotiv unique

  • Inotiv pairs preclinical CRO services with research models and analytical capabilities.
  • July 2026 emergence from Chapter 11 cut about $326 million of debt.
  • Its VUGENE collaboration adds AI bioinformatics across Discovery and Translational Sciences.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Pension
  • Life Insurance
  • Wellbeing Program
  • Paid Time Off
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Stock Options
  • Company Equity
  • Conference Attendance Budget
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

20%

1 year growth

20%

2 year growth

20%
Pryor Cashman
Jun 22nd, 2026
Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases.

Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases. Pryor Cashman has been engaged as counsel to Acquiom Agency Services LLC ("Acquiom"), in its roles as (i) DIP Agent for the Debtor-in-Possession Loan Credit Agreement, and (ii) administrative and collateral agent under the Prepetition First Lien Credit Agreement in the Chapter 11 bankruptcy cases of Inotiv, Inc. ("Inotiv") and its affiliated debtors. Inotiv is a contract research organization that provides drug discovery and development services to the pharmaceutical and medical device industries. On June 3, 2026, Inotiv and certain of its affiliates filed for bankruptcy protection in the United States Bankruptcy Court for the Southern District of Texas. The Pryor Cashman team representing Acquiom includes Partner Seth H. Lieberman, Chair of the Bankruptcy, Reorganization, and Creditors' Rights Group and Co-Chair of the Corporate Trust Practice; Partner Patrick Sibley, Co-Chair of the Corporate Trust Practice; Partner David W. Smith; Counsels Arsala Kidwai and Andrew S. Richmond; and Associate Daniel Brenner.seth Related people. Related services & industries. Firm Highlights Slide 1 of 10

Inotiv
Jun 3rd, 2026
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company’s existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implement a comprehensive recapitalization transaction that will strengthen its capital structure. To implement the transaction, Inotiv has filed a voluntary, prepackaged chapter

StockTitan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

StockTitan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...